FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mats Karlsson

Research Profile

Concepts & Ideas

Physiology

Pharmacokinetics

Activities & Behaviors

Chemicals & Drugs

Antineoplastic Agents

Procedures

Phenomena

Metabolic Clearance Rate

Disorders

Neutropenia

Co-author Network

Publications

TOP 3
Maria C Kjellsson; Norman A Mazer; Valérie F Cosson; Nicolas Frey; Mats O Karlsson
A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment.
Elin M Svensson; Francesca Aweeka; Kelly E Dooley; Florence Marzan; Jeong-Gun Park; Mats O Karlsson
Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis.
Rocío Lledó-García; Norman A Mazer; Mats O Karlsson
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mats Karlsson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maria C Kjellsson; Norman A Mazer; Valérie F Cosson; Nicolas Frey; Mats O Karlsson
A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment.
Journal of clinical pharmacology 2013;53(6):589-600.
2013: Elin M Svensson; Francesca Aweeka; Kelly E Dooley; Florence Marzan; Jeong-Gun Park; Mats O Karlsson
Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis.
Antimicrobial agents and chemotherapy 2013;57(6):2780-7.
2013: Rocío Lledó-García; Norman A Mazer; Mats O Karlsson
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.
Journal of pharmacokinetics and pharmacodynamics 2013;40(2):129-42.
2013: Karen B Schneck; Robert Bauer; Mats O Karlsson; Xin Zhang; Vikram P Sinha
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model.
Journal of pharmacokinetics and pharmacodynamics 2013;40(1):67-80.
2013: Emmanuel Chigutsa; Paolo Denti; Carl M J Kirkpatrick; Gary Maartens; Helen McIlleron; Kashyap Patel; Marianne Visser; Mats O Karlsson
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
Antimicrobial agents and chemotherapy 2013;57(2):789-95.
2013: Steve Choy; Emilie Hénin; Maria C Kjellsson; Jan-Stefan van der Walt; Mats O Karlsson
Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.
Journal of pharmacokinetics and pharmacodynamics 2013;40(1):1-10.
2012: Mats O Karlsson; Martin Bergstrand
Letter to the editor regarding: "a reduction in between subject variability is not mandatory for selecting a new covariate".
Journal of pharmacokinetics and pharmacodynamics 2012;39(6):725-6; author reply 727.
2012: Xu Steven Xu; Min Yuan; Adrian Dunne; Mats O Karlsson; Partha Nandy; An Vermeulen
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.
The AAPS journal 2012;14(4):927-36.
2012: Petra M Jauslin; Mats O Karlsson; Nicolas Frey
Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model.
Journal of clinical pharmacology 2012;52(12):1861-71.
2012: Joakim Nyberg; Eric A Strömberg; Sebastian Ueckert; Stefanie Hennig; Mats O Karlsson; Andrew C Hooker
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool.
Computer methods and programs in biomedicine 2012;108(2):789-805.
2012: Rocío Lledó-García; Dominik E Uehlinger; Robert M Kalicki; Mats O Karlsson
Modeling of red blood cell life-spans in hematologically normal populations.
Journal of pharmacokinetics and pharmacodynamics 2012;39(5):453-62.
2012: Elodie L Plan; Mats O Karlsson; Alan Maloney; France Mentré; Julie Bertrand
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.
The AAPS journal 2012;14(3):420-32.
2012: Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Alwin Huitema; Mats O Karlsson; Tamara Kredo; Jean B Nachega; Paolo Denti
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
British journal of clinical pharmacology 2012;74(3):465-76.
2012: Bengt Hamrén; K Peter Ohman; Maria K Svensson; Mats O Karlsson
Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.
Journal of clinical pharmacology 2012;52(9):1317-27.
2012: Chao Zhang; Paolo Denti; Mats O Karlsson; Yuan Ren; Peter Smith; Jan-Stefan van der Walt; Helen McIlleron
Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.
Therapeutic drug monitoring 2012;34(4):481-4.
2012: Matts Kågedal; Zsolt Cselényi; Andrew C Hooker; Siv Jönsson; Svante Nyberg; Patrick Raboisson; Per Stenkrona; Mats O Karlsson
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers.
NeuroImage 2012;61(4):849-56.
2012: Maud Delattre; Mats O Karlsson; Raymond Miller; Radojka M Savic; Marc Lavielle
Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.
Journal of pharmacokinetics and pharmacodynamics 2012;39(3):263-71.
2012: Lena E Friberg; Mats O Karlsson; Patanjali Ravva; Ping Liu
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.
Antimicrobial agents and chemotherapy 2012;56(6):3032-42.
2012: Joakim Nyberg; Mats O Karlsson; Martin Bergstrand; Richard Höglund; Andrew C Hooker
Serial correlation in optimal design for nonlinear mixed effects models.
Journal of pharmacokinetics and pharmacodynamics 2012;39(3):239-49.
2012: Camille Vong; Joakim Nyberg; Martin Bergstrand; Mats O Karlsson
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.
The AAPS journal 2012;14(2):176-86.
2012: Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.
The AAPS journal 2012;14(2):155-63.
2012: Jae Eun Ahn; Mats O Karlsson; Elodie L Plan; Raymond Miller
Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment.
Journal of clinical pharmacology 2012;52(6):880-92.
2012: E L Plan; Maria Laura Sargentini-Maier; Armel Stockis; J-P Elshoff; Mats O Karlsson
Likert pain score modeling: a Markov integer model and an autoregressive continuous model.
Clinical pharmacology and therapeutics 2012;91(5):820-8.
2012: Chao Zhang; Ulrika S H Simonsson; Eric Decloedt; Paolo Denti; Mats O Karlsson; Gary Maartens; Helen McIlleron
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
British journal of clinical pharmacology 2012;73(5):758-67.
2012: Dongwoo Kang; Kyun-Seop Bae; Brett E Houk; Radojka M Savic; Mats O Karlsson
Standard Error of Empirical Bayes Estimate in NONMEM® VI.
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2012;16(2):97-106.
2012: B D Lacroix; Lena E Friberg; Mats O Karlsson
Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.
Journal of pharmacokinetics and pharmacodynamics 2012;39(2):177-93.
2012: Angelica Linnea Quartino; Lena E Friberg; Mats O Karlsson
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
Investigational new drugs 2012;30(2):833-45.
2012: Martin Bergstrand; Ulf G Eriksson; Erik Söderlind; Werner Weitschies; Mats O Karlsson
A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.
Pharmaceutical research 2012;29(3):695-706.
2012: Stefanie Hennig; Andrew C Hooker; Kalle Hoppu; Janne T Backman; Samuel Fanta; Joakim Nyberg; Mats O Karlsson
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin.
Journal of clinical pharmacology 2012;52(3):347-60.
2012: Martin Bergstrand; Ulf G Eriksson; Erik Söderlind; Werner Weitschies; Mats O Karlsson
A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.
Pharmaceutical research 2012;29(2):574-84.
2012: Chao Zhang; Ulrika S H Simonsson; Mats O Karlsson; Helen McIlleron; Yuan Ren; Jan-Stefan van der Walt; Paolo Denti
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Antiviral therapy 2012;17(1):25-33.
2011: Åsa M Johansson; Mats O Karlsson; Martha Perisoglou; Nicola Hill; Jeremy Whelan; Joseph F Standing
A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Therapeutic drug monitoring 2011;33(6):711-8.
2011: Johan E Wallin; Henryk E Wilczek; Martin Bergstrand; Mats O Karlsson; Per S Nydert; Christine E Staatz
Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
Therapeutic drug monitoring 2011;33(6):663-72.
2011: Elodie L Plan; Jörgen Jensen; Guangli Ma; Mats Någård; Mats O Karlsson
Transient lower esophageal sphincter relaxation pharmacokinetic-pharmacodynamic modeling: count model and repeated time-to-event model.
The Journal of pharmacology and experimental therapeutics 2011;339(3):878-85.
2011: Mirjam N Trame; Mats O Karlsson; Martin Bergstrand; Joachim Boos; Georg Hempel
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6867-77.
2011: Maria C Kjellsson; Daniele Ouellet; Brian Corrigan; Mats O Karlsson
Modeling sleep data for a new drug in development using markov mixed-effects models.
Pharmaceutical research 2011;28(10):2610-27.
2011: Elena Soto; Iñaki F Trocóniz; Jantien Wanders; Jos H Beijnen; Josep María Cendrós; Lena E Friberg; Alwin D R Huitema; Ron J Keizer; Rosendo Obach; Concepción Peraire; Jan H M Schellens; Mats O Karlsson
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Investigational new drugs 2011;29(5):984-95.
2011: Akash Khandelwal; Kajsa Harling; Andrew C Hooker; E Niclas Jonsson; Mats O Karlsson
A fast method for testing covariates in population PK/PD Models.
The AAPS journal 2011;13(3):464-72.
2011: Roberto Bizzotto; Giuseppe De Nicolao; Roberto Gomeni; Andrew Hooker; Enrica Mezzalana; Stefano Zamuner; Mats O Karlsson
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.
The AAPS journal 2011;13(3):445-63.
2011: Siv Jönsson; Mats O Karlsson; Alistair Davidse; Ulrika S H Simonsson; Peter Smith; Jan-Stefan Van der Walt; Justin Wilkins; Helen McIlleron
Population pharmacokinetics of ethambutol in South African tuberculosis patients.
Antimicrobial agents and chemotherapy 2011;55(9):4230-7.
2011: Martin Bergstrand; Andrew C Hooker; Johan E Wallin; Mats O Karlsson
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.
The AAPS journal 2011;13(2):143-51.
2011: Alex Bogason; Angelica L Quartino; Pierre Lafolie; Michèle Masquelier; Mats O Karlsson; Christer Paul; Astrid Gruber; Sigurd Vitols
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
British journal of clinical pharmacology 2011;71(4):514-21.
2011: Matti Kivikko; Stig Sundberg; Mats O Karlsson; Pasi Pohjanjousi; Wilson S Colucci
Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
Scandinavian cardiovascular journal : SCJ 2011;45(2):86-90.
2011: Jerker Westin; Dag Nyholm; Sven Pålhagen; Thomas Willows; Torgny Groth; Mark Dougherty; Mats O Karlsson
A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
Clinical neuropharmacology 2011;34(2):61-5.
2011: Kristin E Karlsson; Elodie L Plan; Mats O Karlsson
Performance of three estimation methods in repeated time-to-event modeling.
The AAPS journal 2011;13(1):83-91.
2011: Paul G Baverel; Radojka M Savic; Mats O Karlsson
Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.
Journal of pharmacokinetics and pharmacodynamics 2011;38(1):63-82.
2011: Petra M Jauslin; Nicolas Frey; Mats O Karlsson
Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes.
Journal of clinical pharmacology 2011;51(2):153-64.
2010: Guangli Ma; Lena E Friberg; Gunilla Movin-Osswald; Mats O Karlsson
Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.
British journal of clinical pharmacology 2010;70(6):815-24.
2010: Kristin E Karlsson; Justin J Wilkins; Fredrik Jonsson; Per-Henrik Zingmark; Mats O Karlsson; E Niclas Jonsson
Modeling disease progression in acute stroke using clinical assessment scales.
The AAPS journal 2010;12(4):683-91.
2010: Lena E Friberg; Marie Sandström; Mats O Karlsson
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.
Investigational new drugs 2010;28(6):744-53.
2010: K J F Petersson; Lena E Friberg; Mats O Karlsson
Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM.
Journal of pharmacokinetics and pharmacodynamics 2010;37(5):493-506.
2010: Ron J Keizer; Anubha Gupta; Melvin R Mac Gillavry; Mendel Jansen; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Mats O Karlsson; Alwin D R Huitema
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal of pharmacokinetics and pharmacodynamics 2010;37(4):347-63.
2010: E L Plan; K E Karlsson; Mats O Karlsson
Approaches to simultaneous analysis of frequency and severity of symptoms.
Clinical pharmacology and therapeutics 2010;88(2):255-9.
2010: Jakob Ribbing; Bengt Hamrén; Maria K Svensson; Mats O Karlsson
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Journal of clinical pharmacology 2010;50(8):861-72.
2010: Marcus A Björnsson; Ake Norberg; Sigridur Kalman; Mats O Karlsson; Ulrika S H Simonsson
A two-compartment effect site model describes the bispectral index after different rates of propofol infusion.
Journal of pharmacokinetics and pharmacodynamics 2010;37(3):243-55.
2010: Pankaj Gupta; Lena E Friberg; Mats O Karlsson; Sriram Krishnaswami; Jonathan French
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis.
Journal of clinical pharmacology 2010;50(6):679-87.
2010: C Steven Ernest; Andrew C Hooker; Mats O Karlsson
Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression.
Pharmaceutical research 2010;27(5):866-77.
2010: Samuel Fanta; Siv Jönsson; Mats O Karlsson; Mikko Niemi; Christer Holmberg; Kalle Hoppu; Janne T Backman
Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.
Journal of clinical pharmacology 2010;50(5):581-97.
2010: Roberto Bizzotto; Stefano Zamuner; Giuseppe De Nicolao; Mats O Karlsson; Roberto Gomeni
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients.
Journal of pharmacokinetics and pharmacodynamics 2010;37(2):137-55.
2010: Emma K Hansson; Johan E Wallin; Henrik Lindman; Marie Sandström; Mats O Karlsson; Lena E Friberg
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Cancer chemotherapy and pharmacology 2010;65(5):839-48.
2010: Johan E Wallin; Lena E Friberg; Mats O Karlsson
Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Basic & clinical pharmacology & toxicology 2010;106(3):234-42.
2010: Hanna E Silber; Petra M Jauslin; Nicolas Frey; Mats O Karlsson
An integrated model for the glucose-insulin system.
Basic & clinical pharmacology & toxicology 2010;106(3):189-94.
2010: Hanna E Silber; Nicolas Frey; Mats O Karlsson
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers.
Journal of clinical pharmacology 2010;50(3):246-56.
2010: Anthe S Zandvliet; Mats O Karlsson; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
Investigational new drugs 2010;28(1):61-75.
2010: Jean-Louis Steimer; Svein G Dahl; Dinesh P de Alwis; Ursula Gundert-Remy; Mats O Karlsson; Jirina Martinkova; Leon Aarons; Hans-Jürgen Ahr; Jean Clairambault; Gilles Freyer; Lena E Friberg; Steven E Kern; Annette Kopp-Schneider; Wolf-Dieter Ludwig; Giuseppe De Nicolao; Maurizio Rocchetti; Iñaki F Troconiz
Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics.
European journal of cancer (Oxford, England : 1990) 2010;46(1):21-32.
2010: Svein G Dahl; Leon Aarons; Ursula Gundert-Remy; Mats O Karlsson; Yves-Jacques Schneider; Jean-Louis Steimer; Iñaki F Trocóniz
Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework.
Basic & clinical pharmacology & toxicology 2010;106(1):2-12.
2009: Iñaki F Trocóniz; Elodie L Plan; Raymond Miller; Mats O Karlsson
Modelling overdispersion and Markovian features in count data.
Journal of pharmacokinetics and pharmacodynamics 2009;36(5):461-77.
2009: Radojka M Savic; Mats O Karlsson
Evaluation of an extended grid method for estimation using nonparametric distributions.
The AAPS journal 2009;11(3):615-27.
2009: Radojka M Savic; Mats O Karlsson
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.
The AAPS journal 2009;11(3):558-69.
2009: Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Semiparametric distributions with estimated shape parameters.
Pharmaceutical research 2009;26(9):2174-85.
2009: Elodie L Plan; Alan Maloney; Iñaki F Trocóniz; Mats O Karlsson
Performance in population models for count data, part I: maximum likelihood approximations.
Journal of pharmacokinetics and pharmacodynamics 2009;36(4):353-66.
2009: Paul G Baverel; Radojka M Savic; Justin J Wilkins; Mats O Karlsson
Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
Journal of pharmacokinetics and pharmacodynamics 2009;36(4):297-315.
2009: M Bergstrand; E Söderlind; W Weitschies; Mats O Karlsson
Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics.
Clinical pharmacology and therapeutics 2009;86(1):77-83.
2009: Lena E Friberg; R de Greef; Thomas Kerbusch; Mats O Karlsson
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.
Clinical pharmacology and therapeutics 2009;86(1):84-91.
2009: R Lledó-García; S Hennig; Mats O Karlsson
Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
Clinical pharmacology and therapeutics 2009;86(1):62-9.
2009: R Lledó-García; S Hennig; Mats O Karlsson
The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials.
Clinical pharmacology and therapeutics 2009;86(1):70-6.
2009: Hanna E Silber; Joakim Nyberg; Andrew C Hooker; Mats O Karlsson
Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.
Journal of pharmacokinetics and pharmacodynamics 2009;36(3):281-95.
2009: Martin Bergstrand; Mats O Karlsson
Handling data below the limit of quantification in mixed effect models.
The AAPS journal 2009;11(2):371-80.
2009: Radojka M Savic; Maria C Kjellsson; Mats O Karlsson
Evaluation of the nonparametric estimation method in NONMEM VI.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2009;37(1):27-35.
2009: Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Simultaneous optimal experimental design on dose and sample times.
Journal of pharmacokinetics and pharmacodynamics 2009;36(2):125-45.
2009: Lena E Friberg; A M Vermeulen; K J F Petersson; Mats O Karlsson
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.
Clinical pharmacology and therapeutics 2009;85(4):409-17.
2009: Kristin C Carlsson; Radojka M Savić; Andrew C Hooker; Mats O Karlsson
Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.
The AAPS journal 2009;11(1):148-54.
2009: Stefanie Hennig; Joakim Nyberg; Andrew C Hooker; Mats O Karlsson
Trial treatment length optimization with an emphasis on disease progression studies.
Journal of clinical pharmacology 2009;49(3):323-35.
2009: Johan E Wallin; Lena E Friberg; Mats O Karlsson
A tool for neutrophil guided dose adaptation in chemotherapy.
Computer methods and programs in biomedicine 2009;93(3):283-91.
2009: Mats O Karlsson; Irja Lutsar; Peter A Milligan
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.
Antimicrobial agents and chemotherapy 2009;53(3):935-44.
2009: Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
Journal of pharmacokinetics and pharmacodynamics 2009;36(1):81-99.
2009: Kristin Cecilie Carlsson; Margunn van de Schootbrugge; Heidi Oien Eriksen; Enrica Ratti Moberg; Mats O Karlsson; Nils Ove Hoem
A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling.
Therapeutic drug monitoring 2009;31(1):86-94.
2009: Anders Lannergård; Anders Viberg; Otto Cars; Mats O Karlsson; Marie Sandström; Anders Larsson
The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy.
Scandinavian journal of infectious diseases 2009;41(9):663-71.
2008: Anders Viberg; Otto Cars; Mats O Karlsson; Siv Jönsson
Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.
Journal of clinical pharmacology 2008;48(11):1270-81.
2008: Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Likelihood based approaches to handling data below the quantification limit using NONMEM VI.
Journal of pharmacokinetics and pharmacodynamics 2008;35(4):401-21.
2008: A C Hooker; A J Ten Tije; Michael A Carducci; James E Weber; Elizabeth Garrett-Mayer; H Gelderblom; W P McGuire; Jaap Verweij; Mats O Karlsson; S D Baker
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
Clinical pharmacology and therapeutics 2008;84(1):111-8.
2008: M O Magnusson; Marja-Liisa Dahl; Jonas Cederberg; Mats O Karlsson; Rikard Sandström
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Clinical pharmacology and therapeutics 2008;84(1):52-62.
2008: Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Approaches to handling pharmacodynamic baseline responses.
Journal of pharmacokinetics and pharmacodynamics 2008;35(3):269-83.
2008: Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
Antimicrobial agents and chemotherapy 2008;52(6):2138-48.
2008: Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.
British journal of clinical pharmacology 2008;65(6):855-63.
2008: Doaa A Elsherbiny; Sara A Asimus; Mats O Karlsson; Michael Ashton; Ulrika S H Simonsson
A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.
Journal of pharmacokinetics and pharmacodynamics 2008;35(2):203-17.
2008: Samuel Fanta; Mikko Niemi; Siv Jönsson; Mats O Karlsson; Christer Holmberg; Pertti J Neuvonen; Kalle Hoppu; Janne T Backman
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Pharmacogenetics and genomics 2008;18(2):77-90.
2007: Nielka P H van Erp; Hans Gelderblom; Mats O Karlsson; Jing Li; Ming Zhao; Jan Ouwerkerk; J W R Nortier; Henk-Jan Guchelaar; Sharyn D Baker; Alex Sparreboom
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7394-400.
2007: Andrew C Hooker; Christine E Staatz; Mats O Karlsson
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.
Pharmaceutical research 2007;24(12):2187-97.
2007: Petra M Jauslin; Hanna E Silber; Nicolas Frey; Ronald Gieschke; Ulrika S H Simonsson; Karin Jorga; Mats O Karlsson
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.
Journal of clinical pharmacology 2007;47(10):1244-55.
2007: Alan Maloney; Mats O Karlsson; Ulrika S H Simonsson
Optimal adaptive design in clinical drug development: a simulation example.
Journal of clinical pharmacology 2007;47(10):1231-43.
2007: Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Journal of pharmacokinetics and pharmacodynamics 2007;34(5):711-26.
2007: Hanna E Silber; Petra M Jauslin; Nicolas Frey; Ronald Gieschke; Ulrika S H Simonsson; Mats O Karlsson
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations.
Journal of clinical pharmacology 2007;47(9):1159-71.
2007: Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Randomized exposure-controlled trials; impact of randomization and analysis strategies.
British journal of clinical pharmacology 2007;64(3):266-77.
2007: Angelica Quartino; Mats O Karlsson; Agneta Freijs; Niclas Jonsson; Peter Nygren; Jörgen Kristensen; Elin Lindhagen; Rolf Larsson
Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Journal of clinical pharmacology 2007;47(8):1014-21.
2007: Anna Lönnebo; Anders Grahnén; Mats O Karlsson
An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.
British journal of clinical pharmacology 2007;64(2):125-32.
2007: Mats O Karlsson; Radojka M Savic
Diagnosing model diagnostics.
Clinical pharmacology and therapeutics 2007;82(1):17-20.
2007: Christoffer W Tornøe; Henrik Agersø; Thomas Senderovitz; Henrik A Nielsen; Henrik Madsen; Mats O Karlsson; E Niclas Jonsson
Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
British journal of clinical pharmacology 2007;63(6):648-64.
2007: Elisabet I Nielsen; Anders Viberg; Elisabeth Löwdin; Otto Cars; Mats O Karlsson; Marie Sandström
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
Antimicrobial agents and chemotherapy 2007;51(1):128-36.
2006: Jing Li; Mats O Karlsson; Julie R Brahmer; Avery Spitz; Ming Zhao; Manuel Hidalgo; Sharyn D Baker
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Journal of the National Cancer Institute 2006;98(23):1714-23.
2006: Saadia B Hassan; Henrik Lövborg; Elin Lindhagen; Mats O Karlsson; Rolf Larsson
CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome.
Anticancer research 2006;26(6B):4431-6.
2006: Ole Osterberg; Radojka M Savic; Mats O Karlsson; Ulrika S H Simonsson; Jens Peter Nørgaard; Johan Vande Walle; Henrik Agersø
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.
Journal of clinical pharmacology 2006;46(10):1204-11.
2006: Angela Abelö; Magdalena Andersson; Ann Aurell Holmberg; Mats O Karlsson
Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2006;29(2):91-101.
2006: Charlotte Kloft; Johan Wallin; Anja Henningsson; Etienne Chatelut; Mats O Karlsson
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5481-90.
2006: Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.
British journal of clinical pharmacology 2006;62(3):297-303.
2006: Marie Sandström; Henrik Lindman; Peter Nygren; M Johansson; Jonas Bergh; Mats O Karlsson
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Cancer chemotherapy and pharmacology 2006;58(2):143-56.
2006: Jane E Latz; James J Rusthoven; Mats O Karlsson; Atalanta Ghosh; Robert D Johnson
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Cancer chemotherapy and pharmacology 2006;57(4):427-35.
2006: Jane E Latz; Mats O Karlsson; James J Rusthoven; Atalanta Ghosh; Robert D Johnson
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Cancer chemotherapy and pharmacology 2006;57(4):412-26.
2006: Mats O Magnusson; Mats O Karlsson; Rikard Sandström
A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.
Pharmaceutical research 2006;23(3):521-32.
2006: Sofie Bååthe; Bengt Hamrén; Mats O Karlsson; Maria Wollbratt; Margaretha Grind; Ulf G Eriksson
Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
Clinical pharmacokinetics 2006;45(8):803-19.
2005: Anja Henningsson; Sharon Marsh; Walter J Loos; Mats O Karlsson; Adam Garsa; Klaus Mross; Stephan Mielke; Lucia Viganò; Alberta Locatelli; Jaap Verweij; Alex Sparreboom; howard mcleod
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8097-104.
2005: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
2005: Lena E Friberg; Saadia B Hassan; Elin Lindhagen; Rolf Larsson; Mats O Karlsson
Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(1):163-73.
2005: Siv Jönsson; Mats O Karlsson
Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(1):123-32.
2005: Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.
Journal of pharmacokinetics and pharmacodynamics 2005;32(2):261-81.
2005: Marie Cullberg; Ulf G Eriksson; Karin Wåhlander; Henry Eriksson; Sam Schulman; Mats O Karlsson
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Clinical pharmacology and therapeutics 2005;77(4):279-90.
2005: Mats O Karlsson; Therese Anehall; Lena E Friberg; Anja Henningsson; Charlotte Kloft; Marie Sandström; Rujia Xie
Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
Basic & clinical pharmacology & toxicology 2005;96(3):206-11.
2005: Toufigh Gordi; Rujia Xie; Nguyen V Huong; Dinh Xuan Huong; Mats O Karlsson; Michael Ashton
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.
British journal of clinical pharmacology 2005;59(2):189-98.
2005: Marie Sandström; Henrik Lindman; Peter Nygren; Elisabet Lidbrink; Jonas Bergh; Mats O Karlsson
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):413-21.
2005: Siv Jönsson; Yi-Fang Cheng; Charlotte Edenius; Kennedy R Lees; Tomas Odergren; Mats O Karlsson
Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Clinical pharmacokinetics 2005;44(8):863-78.
2005: Synnöve Lindemalm; Radojka M Savic; Mats O Karlsson; Gunnar Juliusson; Jan Liliemark; Freidoun Albertioni
Application of population pharmacokinetics to cladribine.
BMC pharmacology 2005;5():4.
2005: Saadia Hassan; Sumeer Dhar; Marie Sandström; Dzmitry Arsenau; Marina Budnikova; Igor Lokot; Nikolai Lobanov; Mats O Karlsson; Rolf Larsson; Elin Lindhagen
Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo.
Cancer chemotherapy and pharmacology 2005;55(1):47-54.
2004: Per-Henrik Zingmark; Charlotte Edenius; Mats O Karlsson
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.
British journal of clinical pharmacology 2004;58(4):378-89.
2004: Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.
British journal of clinical pharmacology 2004;58(4):367-77.
2004: Henrik Agersø; Lotte Seiding Larsen; Anders Riis; Ulf Lövgren; Mats O Karlsson; Thomas Senderovitz
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.
British journal of clinical pharmacology 2004;58(4):352-8.
2004: Siv Jönsson; Maria C Kjellsson; Mats O Karlsson
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.
Journal of pharmacokinetics and pharmacodynamics 2004;31(4):299-320.
2004: THOMAS WALSH; Mats O Karlsson; Timothy Driscoll; Adriano Arguedas; Peter Charles Adamson; Xavier Saez-Llorens; Ajay J Vora; Antonio Arrieta; Jeffrey Blumer; Irja Lutsar; Peter Milligan; Nolan Wood
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Antimicrobial agents and chemotherapy 2004;48(6):2166-72.
2004: Ulrika Wählby; Katalin Matolcsi; Mats O Karlsson; E Niclas Jonsson
Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
Journal of pharmacokinetics and pharmacodynamics 2004;31(1):61-74.
2004: Thomas Kerbusch; Peter A Milligan; Mats O Karlsson
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.
British journal of clinical pharmacology 2004;57(2):170-80.
2004: Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.
The AAPS journal 2004;6(3):e19.
2003: Thomas Kerbusch; Ulrika Wählby; Peter A Milligan; Mats O Karlsson
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.
British journal of clinical pharmacology 2003;56(6):639-52.
2003: Henrik Agersø; Wolfgang Koechling; Magnus Knutsson; Rolf Hjortkjaer; Mats O Karlsson
The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;20(3):335-40.
2003: Ron H J Mathijssen; Sharon Marsh; Mats O Karlsson; Rujia Xie; Sharyn D Baker; Jaap Verweij; Alex Sparreboom; howard mcleod
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3246-53.
2003: Per-Henrik Zingmark; Marianne Ekblom; Tomas Odergren; Tim Ashwood; Patrick D Lyden; Mats O Karlsson; E Niclas Jonsson
Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.
British journal of clinical pharmacology 2003;56(2):173-83.
2003: E Niclas Jonsson; Saila Antila; Lynn McFadyen; Lasse Lehtonen; Mats O Karlsson
Population pharmacokinetics of levosimendan in patients with congestive heart failure.
British journal of clinical pharmacology 2003;55(6):544-51.
2003: Lena E Friberg; Mats O Karlsson
Mechanistic models for myelosuppression.
Investigational new drugs 2003;21(2):183-94.
2003: Anja Henningsson; Alex Sparreboom; Marie Sandström; Agneta Freijs; Rolf Larsson; Jonas Bergh; Peter Nygren; Mats O Karlsson
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
2003: Synnöve Lindemalm; Jan Liliemark; Astrid Gruber; Staffan Eriksson; Mats O Karlsson; Yuying Wang; Freidoun Albertioni
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
Haematologica 2003;88(3):324-32.
2003: Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.
European journal of clinical pharmacology 2003;58(11):747-55.
2003: Ulf G Eriksson; Jaap W Mandema; Mats O Karlsson; Lars Frison; Per Olsson Gisleskog; Ulrika Wählby; Bengt Hamrén; David Gustafsson; Bengt I Eriksson
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Clinical pharmacokinetics 2003;42(7):687-701.
2003: Siv Jönsson; Mats O Karlsson
A rational approach for selection of optimal covariate-based dosing strategies.
Clinical pharmacology and therapeutics 2003;73(1):7-19.
2002: Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4713-21.
2002: Per Olsson Gisleskog; Mats O Karlsson; Stuart L Beal
Use of prior information to stabilize a population data analysis.
Journal of pharmacokinetics and pharmacodynamics 2002;29(5-6):473-505.
2002: Vincent Duval; Mats O Karlsson
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
Pharmaceutical research 2002;19(12):1835-40.
2002: Rujia Xie; Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij; Mats O Karlsson
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Clinical pharmacology and therapeutics 2002;72(3):265-75.
2002: Peter Hovstadius; Rolf Larsson; Elin Jonsson; Torsten Skov; Anne-Marie Kissmeyer; Klaus Krasilnikoff; Jonas Bergh; Mats O Karlsson; Anna Lönnebo; Johan Ahlgren
A Phase I study of CHS 828 in patients with solid tumor malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2843-50.
2002: Angela Abelö; Björn Holstein; Ulf G Eriksson; Johan Gabrielsson; Mats O Karlsson
Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.
Journal of pharmacokinetics and pharmacodynamics 2002;29(4):365-82.
2002: Ulrika S H Svensson; Hassan Alin; Mats O Karlsson; Yngve Bergqvist; Michael Ashton
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.
European journal of clinical pharmacology 2002;58(5):339-51.
2002: Rujia Xie; Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij; Mats O Karlsson
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3293-301.
2002: Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Assessment of type I error rates for the statistical sub-model in NONMEM.
Journal of pharmacokinetics and pharmacodynamics 2002;29(3):251-69.
2002: Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.
AAPS pharmSci 2002;4(4):E27.
2002: Peter A Milligan; Scott F Marshall; Mats O Karlsson
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction.
British journal of clinical pharmacology 2002;53 Suppl 1():45S-52S.
2001: Saadia B Hassan; Elin Jonsson; Rolf Larsson; Mats O Karlsson
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
The Journal of pharmacology and experimental therapeutics 2001;299(3):1140-7.
2001: Angela Abelö; Johan Gabrielsson; B Holstein; Ulf G Eriksson; J Holmberg; Mats O Karlsson
Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2001;14(4):339-46.
2001: Anja Henningsson; Mats O Karlsson; L Viganò; Luca Gianni; Jaap Verweij; Alex Sparreboom
Mechanism-based pharmacokinetic model for paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4065-73.
2001: Marie Sandström; Mats O Karlsson; P Ljungman; Z Hassan; E N Jonsson; C Nilsson; O Ringden; G Oberg; A Bekassy; M Hassan
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Bone marrow transplantation 2001;28(7):657-64.
2001: Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Assessment of actual significance levels for covariate effects in NONMEM.
Journal of pharmacokinetics and pharmacodynamics 2001;28(3):231-52.
2001: Elin Jonsson; Lena E Friberg; Mats O Karlsson; Saadia B Hassan; Peter Nygren; Jörgen Kristensen; B Tholander; Lise Binderup; Rolf Larsson
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.
Cancer letters 2001;162(2):193-200.
2001: Saadia B Hassan; Manuel de la Torre; Peter Nygren; Mats O Karlsson; Rolf Larsson; Elin Jonsson
A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828.
Anti-cancer drugs 2001;12(1):33-42.
2001: Marie Cullberg; Ulf G Eriksson; M Larsson; Mats O Karlsson
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.
British journal of clinical pharmacology 2001;51(1):71-9.
2001: L Brynne; J L McNay; Hans Guenter Schaefer; K Swedberg; C G Wiltse; Mats O Karlsson
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
British journal of clinical pharmacology 2001;51(1):35-43.
2000: Lena E Friberg; CJ Brindley; Mats O Karlsson; A J Devlin
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
European journal of clinical pharmacology 2000;56(8):567-74.
2000: Lena E Friberg; Agneta Freijs; Marie Sandström; Mats O Karlsson
Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
The Journal of pharmacology and experimental therapeutics 2000;295(2):734-40.
2000: Angela Abelö; Ulf G Eriksson; Mats O Karlsson; H Larsson; Johan Gabrielsson
A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
The Journal of pharmacology and experimental therapeutics 2000;295(2):662-9.
2000: L Brynne; LK Paalzow; Mats O Karlsson
Consequence of exercise on the cardiovascular effects of l-propranolol in spontaneously hypertensive rats.
The Journal of pharmacology and experimental therapeutics 2000;294(3):1201-8.
2000: Mats O Karlsson; Rik C Schoemaker; B Kemp; Adam Cohen; J M A van Gerven; B Tuk; C C Peck; Meindert Danhof
A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.
Clinical pharmacology and therapeutics 2000;68(2):175-88.
2000: L E Simonsen; Ulrika Wählby; Marie Sandström; Agneta Freijs; Mats O Karlsson
Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
Anticancer research 2000;20(3A):1519-25.
2000: E Niclas Jonsson; JR Wade; Mats O Karlsson
Nonlinearity detection: advantages of nonlinear mixed-effects modeling.
AAPS pharmSci 2000;2(3):E32.
2000: Elin Jonsson; Lena E Friberg; Mats O Karlsson; Saadia B Hassan; Agneta Freijs; K Hansen; Rolf Larsson
Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.
Cancer chemotherapy and pharmacology 2000;46(6):493-500.
1999: Mats O Karlsson; V Molnar; Agneta Freijs; Peter Nygren; Jonas Bergh; Rolf Larsson
Pharmacokinetic models for the saturable distribution of paclitaxel.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(10):1220-3.
1999: S Sadray; E Niclas Jonsson; Mats O Karlsson
Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.
Pharmaceutical research 1999;16(8):1260-5.
1999: P Olsson Gisleskog; David Hermann; M Hammarlund-Udenaes; Mats O Karlsson
Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1999;8(4):291-9.
1999: L Brynne; LK Paalzow; Mats O Karlsson
Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats.
The Journal of pharmacology and experimental therapeutics 1999;290(2):664-71.
1999: M Gårdmark; L Brynne; Margareta Hammarlund-Udenaes; Mats O Karlsson
Interchangeability and predictive performance of empirical tolerance models.
Clinical pharmacokinetics 1999;36(2):145-67.
1999: Marie Sandström; L E Simonsen; Agneta Freijs; Mats O Karlsson
The pharmacokinetics of epirubicin and docetaxel in combination in rats.
Cancer chemotherapy and pharmacology 1999;44(6):469-74.
1999: E Niclas Jonsson; Mats O Karlsson
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.
Computer methods and programs in biomedicine 1999;58(1):51-64.
1999: Per Olsson Gisleskog; David Hermann; M Hammarlund-Udenaes; Mats O Karlsson
The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.
British journal of clinical pharmacology 1999;47(1):53-8.
1998: Per Olsson Gisleskog; David Hermann; M Hammarlund-Udenaes; Mats O Karlsson
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Clinical pharmacology and therapeutics 1998;64(6):636-47.
1998: E Niclas Jonsson; Mats O Karlsson
Automated covariate model building within NONMEM.
Pharmaceutical research 1998;15(9):1463-8.
1998: L Brynne; Mats O Karlsson; LK Paalzow
Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1152-8.
1998: M Gardmark; Mats O Karlsson; Fredrik Jonsson; Margareta Hammarlund-Udenaes
Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling.
Journal of pharmaceutical sciences 1998;87(7):813-20.
1998: Mats O Karlsson; E Niclas Jonsson; C G Wiltse; JR Wade
Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.
Journal of pharmacokinetics and biopharmaceutics 1998;26(2):207-46.
1998: J S Sidhu; Michael Ashton; Nguyen V Huong; Trinh Ngoc Hai; Mats O Karlsson; ND Sy; E Niclas Jonsson; L D Cong
Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria.
British journal of clinical pharmacology 1998;45(4):347-54.
1998: Mats O Karlsson; JR Wade; Ernest Loumaye; Alain Munafo
The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.
British journal of clinical pharmacology 1998;45(1):13-20.
1998: Mats O Karlsson; V Molnar; Jonas Bergh; Agneta Freijs; Rolf Larsson
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Clinical pharmacology and therapeutics 1998;63(1):11-25.
1997: Mats O Karlsson; JR Wade; Ernest Loumaye; Alain Munafo
A population model for the follicular growth in women treated with follicle stimulating hormone.
Clinical pharmacology and therapeutics 1997;62(6):665-74.
1997: E Niclas Jonsson; JR Wade; G Almqvist; Mats O Karlsson
Discrimination between rival dosing histories.
Pharmaceutical research 1997;14(8):984-91.
1996: M Sandström; Agneta Freijs; Rolf Larsson; P Nygren; M L Fjällskog; Jonas Bergh; Mats O Karlsson
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1581-8.
1996: E Niclas Jonsson; JR Wade; Mats O Karlsson
Comparison of some practical sampling strategies for population pharmacokinetic studies.
Journal of pharmacokinetics and biopharmaceutics 1996;24(2):245-63.
1994: A Lindberg-Freijs; Mats O Karlsson
Dose dependent absorption and linear disposition of cyclosporin A in rat.
Biopharmaceutics & drug disposition 1994;15(1):75-86.
1992: U Bredberg; Mats O Karlsson; Lars Borgstrom
A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans.
Clinical pharmacology and therapeutics 1992;52(3):239-48.
1991: U Bredberg; Mats O Karlsson
In vivo evaluation of the semi-simultaneous method for bioavailability estimation using controlled intravenous infusion as an 'extravascular' route of administration.
Biopharmaceutics & drug disposition 1991;12(8):583-97.
1990: Mats O Karlsson; A Lindberg-Freijs
Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.
Journal of pharmacokinetics and biopharmaceutics 1990;18(4):293-311.
1990: Mats O Karlsson; U Bredberg
Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.
Journal of pharmacokinetics and biopharmaceutics 1990;18(2):103-20.
1990: Mats O Karlsson; B Dahlström
Serum protein binding of noscapine: influence of a reversible hydrolysis.
The Journal of pharmacy and pharmacology 1990;42(2):140-3.
1990: Mats O Karlsson; B Dahlström; S A Eckernäs; M Johansson; A T Alm
Pharmacokinetics of oral noscapine.
European journal of clinical pharmacology 1990;39(3):275-9.
1989: Mats O Karlsson; U Bredberg
Estimation of bioavailability on a single occasion after semisimultaneous drug administration.
Pharmaceutical research 1989;6(9):817-21.
1989: Mats O Karlsson; A Neil
Estimation of ligand binding parameters by simultaneous fitting of association and dissociation data: a Monte Carlo simulation study.
Molecular pharmacology 1989;35(1):59-66.
1988: Mats O Karlsson; A Neil
Estimation of binding parameters by kinetic data analysis: differentiation between one and two binding sites.
European journal of pharmacology 1988;148(1):115-21.
1988: Mats O Karlsson; B Dahlström; A Neil
Characterization of high-affinity binding sites for the antitussive [3H]noscapine in guinea pig brain tissue.
European journal of pharmacology 1988;145(2):195-203.